Mural OncologyMURA
MURA
About: Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Employees: 116
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
278% more call options, than puts
Call options by funds: $185K | Put options by funds: $49K
6.71% less ownership
Funds ownership: 55.43% [Q4 2024] → 48.72% (-6.71%) [Q1 2025]
11% less funds holding
Funds holding: 75 [Q4 2024] → 67 (-8) [Q1 2025]
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
65% less capital invested
Capital invested by funds: $30.4M [Q4 2024] → $10.6M (-$19.9M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for MURA.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Mural Oncology Announces Number of Relevant Securities in Issue
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares with par value US$0.01 each (the “Ordinary Shares”).
Neutral
GlobeNewsWire
2 months ago
FORM 8.1(a) & (b) - Mural Oncology plc
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full name of discloser: Mural Oncology plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.
Positive
Zacks Investment Research
2 months ago
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Neutral
GlobeNewsWire
2 months ago
Mural Oncology Announces Plans to Explore Strategic Alternatives
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
Negative
Benzinga
3 months ago
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
Neutral
GlobeNewsWire
3 months ago
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Neutral
GlobeNewsWire
4 months ago
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025
Neutral
GlobeNewsWire
4 months ago
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.
Neutral
GlobeNewsWire
6 months ago
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
Neutral
GlobeNewsWire
7 months ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 26,300 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,200 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™